Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies.

doi:10.1111/cas.15427

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies.

Cancer science - 1 Aug 2022

Fukuhara Suguru, Oshikawa-Kumade Yuji, Kogure Yasunori, Shingaki Sumito, Kariyazono Hirokazu, Kikukawa Yoshiya, Koya Junji, Saito Yuki, Tabata Mariko, Yoshifuji Kota, Mizuno Kota, Miyagi-Maeshima Akiko, Matsushita Hiromichi, Sugiyama Masanaka, Ogawa Chitose, Inamoto Yoshihiro, Fukuda Takahiro, Sugano Masato, Yamauchi Nobuhiko, Minami Yosuke, Hirata Makoto, Yoshida Teruhiko, Kohno Takashi, Kohsaka Shinji, Mano Hiroyuki, Shiraishi Yuichi, Ogawa Seishi, Izutsu Koji, Kataoka Keisuke

Abstract excerpt

Identification of genetic alterations through next-generation sequencing (NGS) can guide treatment decision-making by providing information on diagnosis, therapy selection, and prognostic stratification in patients with hematological malignancies. Although the utility of NGS-based genomic profiling assays was investigated in hematological malignancies, no assays sufficiently cover driver mutations, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Acute Myeloid Leukemia Research

Share to Feasibility Studies

Share to Genomics

Share to Hematologic Neoplasms

Share to High-Throughput Nucleotide Sequencing

Share to Lymphoma Diagnosis and Treatment

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 35579198
DOI: 10.1111/cas.15427
PMCID: PMC9357666

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies.PMID 35579198Read ↗

Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.Semantic proximity Read ↗

Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical TrialsSemantic proximity Read ↗

The role of next-generation sequencing in hematologic malignanciesSemantic proximity Read ↗

[NGS-based multi-gene panel testing in hematological malignancies: therapeutic significance].Semantic proximity Read ↗

Next-generation sequencing: advances and applications in cancer diagnosisSemantic proximity Read ↗

A genetic profiling guideline to support diagnosis and clinical management of lymphomas.Semantic proximity Read ↗

Lessons from next-generation sequencing analysis in hematological malignanciesSemantic proximity Read ↗

Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasmsSemantic proximity Read ↗

Applications of next-generation sequencing in hematologic malignancies.Semantic proximity Read ↗

Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies.Semantic proximity Read ↗

The Genomic Era of Clinical Oncology: Integrated Genomic Analysis for Precision Cancer CareSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.